NRN1 and esophageal cancer: In 2021, Guo et al. reported that the combination of PI3K inhibitor NVP-BEZ235 with berzosertib increased cytotoxicity in human esophageal cancer (ESCC) cells bearing Neuritin 1 (NRN1) repressed by promoter region methylation [60].